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Abstract Previously we found that the carboxyl-terminal
propeptide of type I collagen (c-propeptide) is a major secretory
protein of MC3T3-E1 osteoblastic cells. In this study, we found
that c-propeptide suppresses collagen synthesis and alkaline
phosphatase activity of MC3T3-E1 osteoblastic cells at the
early-differentiated stage in a dose dependent manner. Mature
osteoblasts did not respond to c-propeptide. These findings imply
that c-propeptide modulates the function of osteoblasts at an
early differentiation stage. Transforming growth factor-L (TGF-
L) is stored in bone and released from bone matrix after
the resorption by osteoclasts. We investigated the effect of
c-propeptide on the action of TGF-L, and found that it enhanced
the effect of TGF-L. We conclude that c-propeptide is a
physiological modulator of TGF-L in bone metabolism. ß 2000
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Transforming growth factor-L (TGF-L) is a growth factor
that modulates the growth and di¡erentiation of various cell
types [1,2]. It is produced by osteoblast [3], and stored in bone
(200 Wg/kg tissue weight) in a latent form [4]. TGF-L is re-
leased from bone during bone resorption [5,6], and stimulates
bone formation in vivo [7,8]. However, in osteoblastic di¡er-
entiation, TGF-L has been shown to prevent the expression of
alkaline phosphatase (ALP) and osteocalcin, which are
markers of mature osteoblasts [9,10]. These ¢ndings imply
that the e¡ect of TGF-L on osteoblasts is suppressed when
osteoblastic cells di¡erentiate into the mineralized tissue-form-
ing stage [11].
Recently we observed that a carboxyl-terminal propeptide
of type I collagen (c-propeptide) is a major secretory protein
of osteoblasts, and that c-propeptide is stored in bone matrix
[12]. All collagens are initially produced as precursors, called
procollagen [13], and which contain extra amino- and carbox-
yl-peptides, which are called propeptide [14]. c-Propeptide is
necessary for the formation of the triple helix structure of
collagen [15]. During the conversion of procollagen to colla-
gen, the propeptides are cleaved by a speci¢c protease [16].
These peptides are considered to be readily broken after they
are released from procollagen. However, the amino- and car-
boxyl-terminal propeptides of type I collagen are present in
bone [12,17,18]. It has been reported that c-propeptide sup-
presses collagen synthesis [19,20], and promotes the attach-
ment of osteoblasts [12]. However, its physiological function
in bone metabolism is not known.
MC3T3-E1 osteoblastic cells display various osteoblastic
phenotypes in a sequential manner under the long-term cul-
ture, and form mineralized tissue [21]. However, no mineral-
ization was induced in the absence of ascorbic acid from the
medium [22]. Moreover the expression of osteoblastic pheno-
types is dependent on the production of type I collagen in
osteoblastic cells [23].
In this study we investigated the e¡ect of c-propeptide on
the action of TGF-L on MC3T3-E1 osteoblastic cells, and
found that c-propeptide enhanced the action of TGF-L.
2. Materials and methods
2.1. Biochemicals
125I-labeled TGF-L and TGF-L were purchased from Amersham
Pharmacia Biotech (Tokyo Japan) and Cosmo Bio. (Tokyo, Japan),
respectively. Other reagents were purchased from Wako Pure Chem-
icals (Tokyo, Japan).
2.2. Preparation of c-propeptide from conditioned media of osteoblastic
MC3T3-E1 cells
c-Propeptide was puri¢ed from the conditioned medium of osteo-
blastic MC3T3-E1 cells that formed mineralized tissue as described
previously [12]. Brie£y, the conditioned medium was subjected to
concanavalin A chromatography equilibrated with 0.5 M NaCl/20
mM Tris (pH 7.4), and the bound fraction was eluted from the col-
umn by the above bu¡er containing 0.2 M K-methyl mannoside. The
¢nal puri¢cation was carried out by CM-cellulose chromatography
and Sephacryl S-200 gel ¢ltration, and the purity of c-propeptide
was veri¢ed by SDS-polyacrylamide gel electrophoresis. The fraction
containing c-propeptide was dialyzed against phosphate-bu¡ered sa-
line (PBS), and then it was stored at 320‡C until use. Anti-c-propep-
tide polyclonal antibody was raised as described previously [12].
2.3. Cell culture
The osteoblastic MC3T3-E1 cells were cultured in K minimum es-
sential medium (K MEM) which contains ascorbic acid (50 mg/l), with
10% fetal calf serum (FCS) [24]. Then 1U105 cells were plated in a
35 mm dish and cultured in a humidi¢ed atmosphere of 5% CO2 (v/v)
at 37‡C. They reached the con£uent stage on day 3 after the inocu-
lation, and formed mineralized tissue at days 15^20. The e¡ect of
TGF-L was investigated in the presence of 10% FCS. TGF-L was
dissolved in 17.5 mM acetic acid as a stock solution and was diluted
with the medium to the concentration of 2 ng/ml. Cells were cultured
in TGF-L-containing medium for 24 h, and then biochemical analysis
was carried out.
2.4. Measurement of ALP activity and DNA contents
Cells were washed with PBS to remove serum proteins and were
scraped from culture dishes. Cells were then homogenized in 10 mM
Tris bu¡er (pH 7.6), and the homogenates were used for ALP activity
assay. One unit was estimated to be 1.4 mg of p-nitrophenol liberated
from p-nitrophenyl phosphate in 15 min [25]. To determine DNA
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content, cell pellets were homogenized in 50 mM Na2HPO4/2.0 M
NaCl (pH 7.4) and mixed with bis-benzimide (Hoechst 33258) [26].
The intensity of £uorescence was measured at an excitation wave-
length of 356 nm and emission wavelength of 458 nm. All standard
stock solutions were stored at 320‡C until use.
2.5. Analysis of collagen synthesis
The newly synthesized collagen was revealed as the intensity of
radioactivity of collagenase-digestible protein (CDP), which was mea-
sured by the bacterial collagenase digestion assay [27]. Brie£y, osteo-
blastic MC3T3-E1 cells were cultured in medium containing 10 WCi of
[3H]proline and 10% FCS for the last 4 h of a 24 h culture, and cell-
matrix layers were digested by highly puri¢ed bacterial collagenase
(Advance Biofactures Corporation, Form III). Then 10% trichloro-
acetic acid and 1% tannic acid were added to the reaction mixture,
and were maintained at 4‡C overnight. After centrifugation at 12 000
rpm for 10 min at 4‡C, the radioactivity of the supernatant was
determined using a liquid scintillation counter.
2.6. TGF-L binding assay
For this assay, 2.5U105 cells were seeded on a 48 multiwell plate,
and cultured until they attached completely. Then cells were washed
with PBS three times and incubated for 20 min with PBS preheated at
37‡C and containing 5 mg/ml of bovine serum albumin. After the cells
were washed with ice-cold PBS, binding assays were performed in the
presence of 0.2 ml/well of ice-cold serum-free medium containing an
appropriate concentration of 125I-labeled TGF-L, and 0.1% bovine
serum albumin. Cells were maintained at 4‡C for 1 h under shaking,
and incubation was terminated by gentle aspiration of the medium
and washing cells four times with ice-cold PBS. Bound radioactivity
was measured in a gamma counter after solubilization of cells by
incubation for 10 min with 0.5 ml of 1% Triton X-100 in PBS, fol-
lowed by 0.5 ml of PBS alone. Non-speci¢c binding was measured in
the presence of 125I-labeled TGF-L and a 100-fold excess amount of
TGF-L. All binding assays were carried out in duplicate and experi-
ments were repeated twice.
3. Results
3.1. The e¡ects of c-propeptide on the collagen synthesis and
ALP activity of MC3T3-E1 osteoblastic cells
We investigated the e¡ects of c-propeptide on collagen syn-
thesis and the ALP activity, which are the di¡erentiation-as-
sociated phenotypes of osteoblast [28], of MC3T3-E1 osteo-
blastic cells. The cells formed mineralized nodules at days 15^
20 after reaching con£uence. MC3T3-E1 osteoblastic cells cul-
tured for 5 days and 20 days after con£uence (designated
preosteoblasts or osteoblasts, respectively, in this article)
were treated with 20 or 40 nM c-propeptide for 24 h, and
the collagen synthesis and the ALP activity were examined.
In preosteoblasts, collagen synthesis and ALP activity were
downregulated by c-propeptide in a dose dependent manner
(Table 1). The inhibition of collagen synthesis was consistent
with previous ¢ndings [19,20]. However, neither parameter
was a¡ected by c-propeptide in osteoblasts (Table 1).
3.2. The e¡ect of c-propeptide on the action of TGF-L on
MC3T3-E1 osteoblastic cells
It has been reported that TGF-L suppresses ALP activity in
MC3T3-E1 osteoblastic cell [29], and we found that c-propep-
tide inhibited ALP activity. Thus we investigated the e¡ect of
c-propeptide on the action of TGF-L. TGF-L suppressed the
ALP activity of MC3T3-E1 osteoblastic cells ; however, the
magnitude of inhibition was weak in osteoblasts compared
with preosteoblasts (Fig. 1). When c-propeptide was added
to the medium containing TGF-L, the enzyme activity was
downregulated in a dose dependent manner, and the enzyme
activity was additively inhibited by TGF-L and c-propeptide
in preosteoblasts (Fig. 1). In the presence of TGF-L (2 ng/ml)
and c-propeptide (40 nM), ALP activity showed 50% inhibi-
tion (Fig. 1). On the other hand, c-propeptide did not a¡ect
the action of TGF-L in osteoblasts (Fig. 1). To con¢rm that
the e¡ect of c-propeptide was speci¢c, cells were cultured with
anti-c-propeptide antibody in medium containing TGF-L (2
ng/ml) and c-propeptide (40 nM). This treatment resulted in
recovery of ALP activity (Table 2).
Table 1
The e¡ect of c-propeptide on collagen synthesis and ALP activity of preosteoblast and osteoblast
c-Propeptide (nM) CDP (U104 dpm/matrix) ALP activity (IU/mg DNA)
Preosteoblast (5 days culture after con£uence) 0 1.9 þ 0.32 28.7 þ 2.1
20 1.7 þ 0.24 25.1 þ 2.9
40 1.5 þ 0.21a 21.3 þ 2.6a
Osteoblast (20 days culture after con£uence) 0 7.8 þ 0.25 70.0 þ 10.5
20 7.7 þ 0.22 72.2 þ 11.3
40 7.8 þ 0.23 71.5 þ 11.0
Values are evaluated from four dishes and shown as mean þ S.D.
aP6 0.05 vs. vehicle by Student’s t-test.
Fig. 1. The e¡ect of c-propeptide on the action of TGF-L to ALP
activity in preosteoblasts and osteoblasts. Preosteoblats that were
cultured for 5 days after con£uence (solid bars) and osteoblasts that
were cultured for 20 days after con£uence (open bars) were treated
with TGF-L and c-propeptide for 24 h. Data were evaluated from
four dishes and shown as mean þ S.D. **P6 0.01 by Student’s t-
test.
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3.3. The a⁄nity of TGF-L to its receptors after treatment with
c-propeptide
The action of TGF-L is expressed by the interaction of
TGF-L with its receptor on the cell membrane. There are
three types of receptors, Type I, Type II and Betaglycan
[30,31]. The a⁄nity of TGF-L to its receptors is reduced after
long-term cultures of MC3T3-E1 osteoblastic cell [11]. There-
fore we investigated the a⁄nity of TGF-L to receptors in the
presence of c-propeptide by Scatchard analysis, and found
that preosteoblasts cultured with c-propeptide (40 nM),
showed higher a⁄nity to TGF-L than cells treated with the
vehicle (Fig. 2). These ¢ndings indicated that the action of
TGF-L was enhanced in the presence of c-propeptide in pre-
osteoblasts by the increased a⁄nity of TGF-L to its receptor.
4. Discussion
The c-propeptide is a major secretory protein of osteoblasts
[12]. It has been postulated that c-propeptide suppresses col-
lagen synthesis in a feedback manner. In IMR-90 ¢broblasts,
40 nM c-propeptide causes 80% reduction of collagen synthe-
sis, while the synthesis of non-collagenous proteins is not af-
fected [32]. Our result that c-propeptide suppressed collagen
synthesis was consistent with previous ¢ndings. Furthermore,
c-propeptide suppressed ALP activity dose dependently in
preosteoblasts. This enzyme inhibition may have been due
to the suppression of collagen synthesis, because ALP activity
is markedly suppressed when either eliminating ascorbic acid
or adding a collagen-synthesis inhibitor that inhibits collagen
synthesis [33]. However, we could not exclude the possibility
that the suppression of ALP activity by c-propeptide may be
due to the change of culture conditions. Therefore, further
investigation is necessary for clearing the mechanism of the
e¡ect of c-propeptide on ALP activity.
In mature osteoblasts, c-propeptide in£uenced neither col-
lagen synthesis nor ALP activity. In another study, we have
found that the insensitivity to c-propeptide in mature osteo-
blasts was due to a decrease of the interaction of c-propeptide
with K2L 1 integrin receptor, which is a main receptor for c-
propeptide (manuscript in preparation). The reduced interac-
tion may be due to a decrease of receptor number, because
Lynch et al. reported that L 1 integrin receptor gene expres-
sion is downregulated in a time dependent manner during the
osteoblastic di¡erentiation [34]. Another possibility for the
lower sensitivity in osteoblasts might be the competition of
type I collagen and c-propeptide for K2L 1 integrin receptors.
Collagen and c-propeptide are produced equimolarly during
collagen synthesis. Collagen shows a 20-fold higher a⁄nity to
K2L 1 integrin receptors than c-propeptide [35]. Therefore,
collagen preferentially binds K2L 1 integrin receptors when
collagen and c-propeptide are present simultaneously, and
this competition may reduce the sensitivity of c-propeptide
to osteoblasts.
TGF-L is one of the abundant growth factors present in
bone matrix, and it is likely that TGF-L has a crucial role
in linking bone formation and bone resorption [36]. On the
other hand, TGF-L has been reported to inhibit ALP activity
in MC3T3-E1 osteoblastic cells [9,29]. These ¢ndings are con-
sistent with our results. TGF-L (2ng/ml) suppressed ALP ac-
tivity in preosteoblasts ; however, the inhibition was weaker in
osteoblasts. This di¡erence might be due to the reduction of
accessibility of TGF-L to its receptor [11]. Takeuchi et al.
found that the expression of type II TGF-L receptor, which
is a main receptor in osteoblasts, is not reduced in osteoblastic
di¡erentiation, and the lesser accessibility might be due to (1)
matrix proteins binding TGF-L, or (2) matrix proteins mask-
ing TGF-L receptors [11].
Next we investigated the e¡ect of c-propeptide on the action
of TGF-L on ALP activity in preosteoblasts. c-Propeptide
additively inhibited ALP activity and the inhibition of enzyme
activity by the c-propeptide increased in a dose dependent
manner. These e¡ects of c-propeptide may be due to the sup-
pression of collagen synthesis. c-Propeptide binds K2L 1 in-
tegrin receptors and inhibits collagen synthesis in a pretran-
scriptional or posttranscriptional manner [19,20,35]. Collagen
synthesis and osteoblastic di¡erentiation are tightly corre-
lated, because the inhibition of collagen synthesis suppresses
osteoblastic di¡erentiation [22,23,33]. Furthermore, type I col-
Table 2







ALP activity (IU/mg DNA)
Preosteoblast (5 days culture after con£uence) 2 0 3 18.8 þ 2.3
2 40 3 12.3 þ 2.8
2 40 + 20.9 þ 3.7
Values are evaluated from four dishes and shown as mean þ S.D.
Fig. 2. Scatchard plot analysis of 125I-labeled TGF-L binding to
MC3T3-E1 osteoblastic cells. 2.5U105 cells that were cultured for
5 days after con£uence were cultured for 1 h at 4‡C in the presence
of various concentrations of 125I-labeled TGF-L. Each data point
represents the mean of duplicate determination, and the experiments
were repeated twice.
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lagen supports the expression of osteoblastic phenotypes [34].
Therefore, c-propeptide might retard the osteoblastic di¡er-
entiation of preosteoblasts, which was shown as the suppres-
sion of ALP activity. The cells treated with c-propeptide
showed higher a⁄nity to TGF-L than cells treated with the
vehicle (Fig. 2), and this higher a⁄nity may cause the higher
inhibition of ALP activity by TGF-L. These ¢ndings imply
that c-propeptide^integrin interaction may alter the a⁄nity
of TGF-L to its receptor in preosteoblasts.
On the other hand, there is a possibility that the inhibition
of ALP activity by TGF-L and c-propeptide are independent
phenomena. However, analysis of the binding of TGF-L to its
receptor in our study implied that the binding of TGF-L to
cells was in£uenced by c-propeptide^integrin interaction.
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